Literature DB >> 25978198

Common questions about the management of gastroesophageal reflux disease.

William D Anderson1, Scott M Strayer1, Shane R Mull1.   

Abstract

Common questions that arise regarding treatment of gastroesophageal reflux disease (GERD) include which medications are most effective, when surgery may be indicated, which patients should be screened for Barrett esophagus and Helicobacter pylori infection, and which adverse effects occur with these medications. Proton pump inhibitors (PPIs) are the most effective medical therapy, and all PPIs provide similar relief of GERD symptoms. There is insufficient evidence to recommend testing for H. pylori in patients with GERD. In the absence of alarm symptoms, endoscopy is not necessary to make an initial diagnosis of GERD. Patients with alarm symptoms require endoscopy. Screening for Barrett esophagus is not routinely recommended, but may be considered in white men 50 years or older who have had GERD symptoms for at least five years. Symptom remission rates in patients with chronic GERD are similar in those who undergo surgery vs. medical management. PPI therapy has been associated with an increased risk of hip fracture, hypomagnesemia, community-acquired pneumonia, vitamin B12 deficiency, and Clostridium difficile infection.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25978198

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  6 in total

1.  Impedance-pH monitoring on medications does not reliably confirm the presence of gastroesophageal reflux disease in patients referred for antireflux surgery.

Authors:  Marc A Ward; Christy M Dunst; Ezra N Teitelbaum; Valerie J Halpin; Kevin M Reavis; Lee L Swanström; Steven R DeMeester
Journal:  Surg Endosc       Date:  2017-08-04       Impact factor: 4.584

Review 2.  Surgical Treatment of Gastroesophageal Reflux Disease.

Authors:  Francisco Schlottmann; Fernando A Herbella; Marco E Allaix; Fabrizio Rebecchi; Marco G Patti
Journal:  World J Surg       Date:  2017-07       Impact factor: 3.352

Review 3.  Proton pump inhibitors for the treatment of patients with erosive esophagitis and gastroesophageal reflux disease: current evidence and safety of dexlansoprazole.

Authors:  Joseph Mermelstein; Alanna Chait Mermelstein; Maxwell M Chait
Journal:  Clin Exp Gastroenterol       Date:  2016-07-13

4.  Nurse-Led, Shared Medical Appointments for Common Gastrointestinal Conditions-Improving Outcomes Through Collaboration With Primary Care in the Medical Home: A Prospective Observational Study.

Authors:  Kerri L Novak; Jennifer Halasz; Christopher Andrews; Colleen Johnston; Willem Schoombee; Divine Tanyingoh; Gilaad G Kaplan; Sander Veldhuyzen van Zanten; Mark Swain
Journal:  J Can Assoc Gastroenterol       Date:  2018-10-24

Review 5.  Thailand guideline 2020 for medical management of gastroesophageal reflux disease.

Authors:  Monthira Maneerattanaporn; Rapat Pittayanon; Tanisa Patcharatrakul; Chalermrat Bunchorntavakul; Siam Sirinthornpanya; Panyavee Pitisuttithum; Asawin Sudcharoen; Uayporn Kaosombatwattana; Kawin Tangvoraphongchai; Reawika Chaikomin; Kamin Harinwan; Karjpong Techathuvanan; Sawangpong Jandee; Phuripong Kijdamrongthum; Anupong Tangaroonsanti; Kulthep Rattanakovit; Sakkarin Chirapongsathorn; Sutep Gonlachanvit; Surapol Surangsrirat; Duangporn Werawatganon; Kitti Chunlertrith; Varocha Mahachai; Somchai Leelakusolvong; Wanich Piyanirun
Journal:  J Gastroenterol Hepatol       Date:  2022-01-25       Impact factor: 4.369

Review 6.  Helicobacter Pylori and Gastric Cancer: Clinical Aspects.

Authors:  Zhi-Qiang Song; Li-Ya Zhou
Journal:  Chin Med J (Engl)       Date:  2015-11-20       Impact factor: 2.628

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.